NigerTuberculosis profile
Population  2014 19 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.4 (2.4–4.5) 18 (13–23)
Mortality (HIV+TB only) 0.47 (0.39–0.56) 2.5 (2–2.9)
Prevalence  (includes HIV+TB) 30 (16–48) 155 (82–250)
Incidence  (includes HIV+TB) 19 (17–21) 98 (87–110)
Incidence (HIV+TB only) 1.5 (1.3–1.8) 7.9 (6.6–9.3)
         
Case detection, all forms (%) 58 (51–65)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
150 (26–270) 110 (27–190)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 7 073   370
Pulmonary, clinically diagnosed 1 698    
Extrapulmonary 1 710    
       
Total new and relapse 10 851    
Previously treated, excluding relapses 251    
Total cases notified 11 102    
Among 7 073 new cases:
96 (1%) cases aged under 15 years; male:female ratio: 3.0
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 (<1%) 86 (14%) 87
Laboratory-confirmed RR-/MDR-TB cases     46
Patients started on MDR-TB treatment ***     47
TB/HIV 2014 Number (%)
TB patients with known HIV status 7 056 (64)
HIV-positive TB patients 485 (7)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 76 (16)
HIV-positive TB patients on antiretroviral therapy (ART) 111 (23)
HIV-positive people screened for TB 2 595  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (79) 10 795
Previously treated cases registered in 2013 (73) 635
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (86) 43
XDR-TB cases started on second-line treatment in 2012 (100) 1
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population)  
Drug susceptibility testing (per 5 million population)  
Sites performing Xpert MTB/RIF  
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-06-30 Data: www.who.int/tb/data